Therapie mit Ketoconazol bei Chorioretinopathia Centralis Serosaeine Pilotstudie
Therapie mit Ketoconazol bei Chorioretinopathia Centralis Serosa
eine Pilotstudie
Dokument öffnen (3.1MB)Art der Hochschulschrift
DissertationPrüfungsdatum
08.05.2009Datum der Veröffentlichung
15.07.2009Erstgutachter
Eter, NicoleZweitgutachter
Bauer, RalfMetadaten
Zur Langanzeige
Zitierbare Links 
Inhalt
Ketoconazole in the treatment of Central Serous Chorioretinopathy : A pilot study
Purpose: The aim of this study is to evaluate a possible effect of systemic Ketoconazole on visual acuity (VA) and retinal thickness in patients with acute central serous chorioretinopathy (CSCR).
Materials and Methods: 15 consecutive patients were treated with Ketoconazole 200 mg/d over a period of 4 weeks, while the other 15 patients served as control group. Baseline examination and review after 4 weeks included VA testing and measurement of neuroretinal or pigment epithelial detachment by optical coherence tomography (OCT). Fluorescein angiography was performed to verify the diagnosis.
Results: At baseline, mean VA in Snellen units was 0.6±0.2 (Log MAR 0.2±0.7) in the treatment group and 0.7±0.3 (Log MAR 0.2±0.5) in the control group. On OCT, mean neuroretinal or pigment epithelial detachment measured 288±163 µm in the Ketoconazole group and 225±51 µm in the control group, respectively. Four weeks later, mean VA improved in both groups. On OCT, neuroretinal or pigment epithelial detachment decreased also in the treatment group and the control group. The differences were statistically not significant.
Conclusion: While a pharmacological decrease in endogenous cortisol synthesis appears to be a rational approach in the treatment of CSCR, systemic Ketoconazole at 200mg/d was not associated with a significantly better outcome in this preliminary study.
Purpose: The aim of this study is to evaluate a possible effect of systemic Ketoconazole on visual acuity (VA) and retinal thickness in patients with acute central serous chorioretinopathy (CSCR).
Materials and Methods: 15 consecutive patients were treated with Ketoconazole 200 mg/d over a period of 4 weeks, while the other 15 patients served as control group. Baseline examination and review after 4 weeks included VA testing and measurement of neuroretinal or pigment epithelial detachment by optical coherence tomography (OCT). Fluorescein angiography was performed to verify the diagnosis.
Results: At baseline, mean VA in Snellen units was 0.6±0.2 (Log MAR 0.2±0.7) in the treatment group and 0.7±0.3 (Log MAR 0.2±0.5) in the control group. On OCT, mean neuroretinal or pigment epithelial detachment measured 288±163 µm in the Ketoconazole group and 225±51 µm in the control group, respectively. Four weeks later, mean VA improved in both groups. On OCT, neuroretinal or pigment epithelial detachment decreased also in the treatment group and the control group. The differences were statistically not significant.
Conclusion: While a pharmacological decrease in endogenous cortisol synthesis appears to be a rational approach in the treatment of CSCR, systemic Ketoconazole at 200mg/d was not associated with a significantly better outcome in this preliminary study.
Schlagwörter
Chorioretinopathia Centralis Serosa, CCS, Zentrale seröse Chorioretinopathie, Corticosteroide, Ketoconazol, Central serous chorioretinopathy, CSC, CSCR, corticosteroids, Ketoconazole
Klassifikation (DDC)
610 Medizin, GesundheitGolshahi, Azadeh: Therapie mit Ketoconazol bei Chorioretinopathia Centralis Serosa : eine Pilotstudie. - Bonn, 2009. - Dissertation, Rheinische Friedrich-Wilhelms-Universität Bonn.
Online-Ausgabe in bonndoc: https://nbn-resolving.org/urn:nbn:de:hbz:5N-17838
Online-Ausgabe in bonndoc: https://nbn-resolving.org/urn:nbn:de:hbz:5N-17838
@phdthesis{handle:20.500.11811/3858,
urn: https://nbn-resolving.org/urn:nbn:de:hbz:5N-17838,
author = {{Azadeh Golshahi}},
title = {Therapie mit Ketoconazol bei Chorioretinopathia Centralis Serosa : eine Pilotstudie},
school = {Rheinische Friedrich-Wilhelms-Universität Bonn},
year = 2009,
month = jul,
note = {Ketoconazole in the treatment of Central Serous Chorioretinopathy : A pilot study
Purpose: The aim of this study is to evaluate a possible effect of systemic Ketoconazole on visual acuity (VA) and retinal thickness in patients with acute central serous chorioretinopathy (CSCR).
Materials and Methods: 15 consecutive patients were treated with Ketoconazole 200 mg/d over a period of 4 weeks, while the other 15 patients served as control group. Baseline examination and review after 4 weeks included VA testing and measurement of neuroretinal or pigment epithelial detachment by optical coherence tomography (OCT). Fluorescein angiography was performed to verify the diagnosis.
Results: At baseline, mean VA in Snellen units was 0.6±0.2 (Log MAR 0.2±0.7) in the treatment group and 0.7±0.3 (Log MAR 0.2±0.5) in the control group. On OCT, mean neuroretinal or pigment epithelial detachment measured 288±163 µm in the Ketoconazole group and 225±51 µm in the control group, respectively. Four weeks later, mean VA improved in both groups. On OCT, neuroretinal or pigment epithelial detachment decreased also in the treatment group and the control group. The differences were statistically not significant.
Conclusion: While a pharmacological decrease in endogenous cortisol synthesis appears to be a rational approach in the treatment of CSCR, systemic Ketoconazole at 200mg/d was not associated with a significantly better outcome in this preliminary study.},
url = {https://hdl.handle.net/20.500.11811/3858}
}
urn: https://nbn-resolving.org/urn:nbn:de:hbz:5N-17838,
author = {{Azadeh Golshahi}},
title = {Therapie mit Ketoconazol bei Chorioretinopathia Centralis Serosa : eine Pilotstudie},
school = {Rheinische Friedrich-Wilhelms-Universität Bonn},
year = 2009,
month = jul,
note = {Ketoconazole in the treatment of Central Serous Chorioretinopathy : A pilot study
Purpose: The aim of this study is to evaluate a possible effect of systemic Ketoconazole on visual acuity (VA) and retinal thickness in patients with acute central serous chorioretinopathy (CSCR).
Materials and Methods: 15 consecutive patients were treated with Ketoconazole 200 mg/d over a period of 4 weeks, while the other 15 patients served as control group. Baseline examination and review after 4 weeks included VA testing and measurement of neuroretinal or pigment epithelial detachment by optical coherence tomography (OCT). Fluorescein angiography was performed to verify the diagnosis.
Results: At baseline, mean VA in Snellen units was 0.6±0.2 (Log MAR 0.2±0.7) in the treatment group and 0.7±0.3 (Log MAR 0.2±0.5) in the control group. On OCT, mean neuroretinal or pigment epithelial detachment measured 288±163 µm in the Ketoconazole group and 225±51 µm in the control group, respectively. Four weeks later, mean VA improved in both groups. On OCT, neuroretinal or pigment epithelial detachment decreased also in the treatment group and the control group. The differences were statistically not significant.
Conclusion: While a pharmacological decrease in endogenous cortisol synthesis appears to be a rational approach in the treatment of CSCR, systemic Ketoconazole at 200mg/d was not associated with a significantly better outcome in this preliminary study.},
url = {https://hdl.handle.net/20.500.11811/3858}
}
Die folgenden Nutzungsbestimmungen sind mit dieser Ressource verbunden:
